Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Food and Drug Administration Safety Over Sequestration Act of 2015
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
Labor, HHS Appropriations,regarding all biopharmaceutical related provisions. Agriculture Appropriations, regarding all biopharmaceutical related provisions. H.R. 1078, FDA Safety Over Sequestration Act, regarding all biopharmaceutical related provisions. No bill, raised awareness about atrial fibrillation and stroke prevention. H/R. 1101, Viral Hepatitis Testing Act, regarding all biopharmaceutical related provisions. H.R.6, 21st Century Cures Initiative, regarding all biopharmaceutical related provisions.
Food and Drug Administration Safety Over Sequestration Act of 2015
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2015 · second_quarter · 2A
Labor, HHS Appropriations,regarding all biopharmaceutical related provisions. Agriculture Appropriations, regarding all biopharmaceutical related provisions. H.R. 1078, FDA Safety Over Sequestration Act, regarding all biopharmaceutical related provisions. No bill, raised awareness about atrial fibrillation and stroke prevention. H/R. 1101, Viral Hepatitis Testing Act, regarding all biopharmaceutical related provisions. H.R.6, 21st Century Cures Initiative, regarding all biopharmaceutical related provisions.
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
Source: Senate LDA
Labor, HHS Appropriations,regarding all biopharmaceutical related provisions. Agriculture Appropriations, regarding all biopharmaceutical related provisions. H.R. 1078, FDA Safety Over Sequestration Act, regarding all biopharmaceutical related provisions. No bill, raised awareness about atrial fibrillation and stroke prevention. H/R. 1101, Viral Hepatitis Testing Act, regarding all biopharmaceutical related provisions. H.R.6, 21st Century Cures Initiative, regarding all biopharmaceutical related provisions.
Food and Drug Administration Safety Over Sequestration Act of 2015
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
Labor, HHS Appropriations,regarding all biopharmaceutical related provisions. Agriculture Appropriations, regarding all biopharmaceutical related provisions. H.R. 1078, FDA Safety Over Sequestration Act, regarding all biopharmaceutical related provisions. No bill, raised awareness about atrial fibrillation and stroke prevention. H/R. 1101, Viral Hepatitis Testing Act, regarding all biopharmaceutical related provisions. No bill, 21st Century Cures Initiative, regarding all biopharmaceutical related provisions.
Protecting Seniors' Access to Medicare Act of 2015
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R. 1416, Cancer Patient Protection Act, regarding all biopharmaceutical related provisions. H.R. 1190 and S. 41, Protecting Seniors' Access to Medicare Act, regarding all biopharmaceutical related provisions. H.R. 2, Medicare Access and CHIP Authorization Act, regarding all biopharmaceutical related provisions
Cancer Patient Protection Act of 2015
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R. 1416, Cancer Patient Protection Act, regarding all biopharmaceutical related provisions. H.R. 1190 and S. 41, Protecting Seniors' Access to Medicare Act, regarding all biopharmaceutical related provisions. H.R. 2, Medicare Access and CHIP Authorization Act, regarding all biopharmaceutical related provisions
Medicare Access and CHIP Reauthorization Act of 2015
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R. 1416, Cancer Patient Protection Act, regarding all biopharmaceutical related provisions. H.R. 1190 and S. 41, Protecting Seniors' Access to Medicare Act, regarding all biopharmaceutical related provisions. H.R. 2, Medicare Access and CHIP Authorization Act, regarding all biopharmaceutical related provisions
21st Century Cures Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
Labor, HHS Appropriations,regarding all biopharmaceutical related provisions. Agriculture Appropriations, regarding all biopharmaceutical related provisions. H.R. 1078, FDA Safety Over Sequestration Act, regarding all biopharmaceutical related provisions. No bill, raised awareness about atrial fibrillation and stroke prevention. H/R. 1101, Viral Hepatitis Testing Act, regarding all biopharmaceutical related provisions. H.R.6, 21st Century Cures Initiative, regarding all biopharmaceutical related provisions.
21st Century Cures Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
Labor, HHS Appropriations,regarding all biopharmaceutical related provisions. Agriculture Appropriations, regarding all biopharmaceutical related provisions. H.R. 1078, FDA Safety Over Sequestration Act, regarding all biopharmaceutical related provisions. No bill, raised awareness about atrial fibrillation and stroke prevention. H/R. 1101, Viral Hepatitis Testing Act, regarding all biopharmaceutical related provisions. H.R.6, 21st Century Cures Initiative, regarding all biopharmaceutical related provisions.
Veterans Travel Tax Relief Act of 2015
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R. 1416, Cancer Patient Protection Act, regarding all biopharmaceutical related provisions. H.R. 1190 and S. 41, Protecting Seniors' Access to Medicare Act, regarding all biopharmaceutical related provisions. H.R. 2, Medicare Access and CHIP Authorization Act, regarding all biopharmaceutical related provisions
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2013
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R. 1325 S. 323, "Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act" regarding all provisions. H.R. 1416, "Cancer Patient Protection Act of 2013," regarding all provisions. H.R. 351 and S. 351, "Protecting Seniors' Access to Medicare Act of 2013," regarding all provisions. H.R. 2010 and S. 1821, SGR Reform, regarding all provisions. H.R. 4301, Protecting Access to Medicare act, regarding all provisions.
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2013
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R. 1325 S. 323, "Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act" regarding all provisions. H.R. 1416, "Cancer Patient Protection Act of 2013," regarding all provisions. H.R. 351 and S. 351, "Protecting Seniors' Access to Medicare Act of 2013," regarding all provisions. H.R. 2010 and S. 1821, SGR Reform, regarding all provisions. H.R. 4301, Protecting Access to Medicare act, regarding all provisions.
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2013
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R. 1325 S. 323, "Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act" regarding all provsions. H.R. 1416, "Cancer Patient Protection Act of 2013," regarding all provisions. H.R. 351 and S. 351, "Protecting Seniors' Access to Medicare Act of 2013," regarding all provisions. H.R. 2010 an dS. 1821, SGR Reform, regarding all provisions.H.R. 4301, Protecting Access to Medicare act, regarding all provisions.
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2013
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R. 1325 S. 323, "Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act" regarding all provisions. H.R. 1416, "Cancer Patient Protection Act of 2013," regarding all provisions. H.R. 351 and S. 351, "Protecting Seniors' Access to Medicare Act of 2013," regarding all provisions. H.R. 2010 and S. 1821, SGR Reform, regarding all provisions.H.R. 4301, Protecting Access to Medicare act, regarding all provisions.
Cancer Patient Protection Act of 2013
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R. 1325 S. 323, "Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act" regarding all provisions. H.R. 1416, "Cancer Patient Protection Act of 2013," regarding all provisions. H.R. 351 and S. 351, "Protecting Seniors' Access to Medicare Act of 2013," regarding all provisions. H.R. 2010 and S. 1821, SGR Reform, regarding all provisions. H.R. 4301, Protecting Access to Medicare act, regarding all provisions.
Cancer Patient Protection Act of 2013
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R. 1325 S. 323, "Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act" regarding all provisions. H.R. 1416, "Cancer Patient Protection Act of 2013," regarding all provisions. H.R. 351 and S. 351, "Protecting Seniors' Access to Medicare Act of 2013," regarding all provisions. H.R. 2010 and S. 1821, SGR Reform, regarding all provisions. H.R. 4301, Protecting Access to Medicare act, regarding all provisions.
Cancer Patient Protection Act of 2013
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R. 1325 S. 323, "Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act" regarding all provsions. H.R. 1416, "Cancer Patient Protection Act of 2013," regarding all provisions. H.R. 351 and S. 351, "Protecting Seniors' Access to Medicare Act of 2013," regarding all provisions. H.R. 2010 an dS. 1821, SGR Reform, regarding all provisions.H.R. 4301, Protecting Access to Medicare act, regarding all provisions.
Cancer Patient Protection Act of 2013
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R. 1325 S. 323, "Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act" regarding all provisions. H.R. 1416, "Cancer Patient Protection Act of 2013," regarding all provisions. H.R. 351 and S. 351, "Protecting Seniors' Access to Medicare Act of 2013," regarding all provisions. H.R. 2010 and S. 1821, SGR Reform, regarding all provisions.H.R. 4301, Protecting Access to Medicare act, regarding all provisions.
Live by the Laws You Write Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R. 1325 S. 323, "Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act" regarding all provsions. H.R. 1416, "Cancer Patient Protection Act of 2013," regarding all provisions. H.R. 351 and S. 351, "Protecting Seniors' Access to Medicare Act of 2013," regarding all provisions. H.R. 2010 an dS. 1821, SGR Reform, regarding all provisions.H.R. 4301, Protecting Access to Medicare act, regarding all provisions.
Live by the Laws You Write Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R. 1325 S. 323, "Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act" regarding all provisions. H.R. 1416, "Cancer Patient Protection Act of 2013," regarding all provisions. H.R. 351 and S. 351, "Protecting Seniors' Access to Medicare Act of 2013," regarding all provisions. H.R. 2010 and S. 1821, SGR Reform, regarding all provisions. H.R. 4301, Protecting Access to Medicare act, regarding all provisions.
Live by the Laws You Write Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R. 1325 S. 323, "Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act" regarding all provisions. H.R. 1416, "Cancer Patient Protection Act of 2013," regarding all provisions. H.R. 351 and S. 351, "Protecting Seniors' Access to Medicare Act of 2013," regarding all provisions. H.R. 2010 and S. 1821, SGR Reform, regarding all provisions. H.R. 4301, Protecting Access to Medicare act, regarding all provisions.
Live by the Laws You Write Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R. 1325 S. 323, "Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act" regarding all provisions. H.R. 1416, "Cancer Patient Protection Act of 2013," regarding all provisions. H.R. 351 and S. 351, "Protecting Seniors' Access to Medicare Act of 2013," regarding all provisions. H.R. 2010 and S. 1821, SGR Reform, regarding all provisions.H.R. 4301, Protecting Access to Medicare act, regarding all provisions.
Food and Drug Administration Safety Over Sequestration Act of 2013
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.J. Res 59, Continuing Appropriations Resolution, regarding all biopharmaceutical related provisions. Labor, HHS Appropriations, regarding all biopharmaceutical related provisions. Agriculture appropriations, regarding all biopharmceutical related provisions. H.R. 2725/S. 1413, FDA Safety over Sequestration Act, regarding all biopharmaceutical user-fees. No-bill, educational meetings regarding atrial fibrillation. No bill - regarding FDA regulatory issues and patent incentives related to the 21st Century Cures Initiative. Health Care Reform implementation - regarding essential health benefits coverage and all biopharmaceutical related provisions. H.R. 3723, Viral Hepatitis Testing Act, regarding all provisions.
Food and Drug Administration Safety Over Sequestration Act of 2013
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.J. Res 59, Continuing Appropriations Resolution, regarding all biopharmaceutical related provisions. Labor, HHS Appropriations, regarding all biopharmaceutical related provisions. Agriculture appropriations, regarding all biopharmceutical related provisions. H.R. 2725/S. 1413, FDA Safety over Sequestration Act, regarding all biopharmaceutical user-fees. No-bill, educational meetings regarding atrial fibrillation. No bill - regarding FDA regulatory issues and patent incentives related to the 21st Century Cures Initiative. Health Care Reform implementation - regarding essential health benefits coverage and all biopharmaceutical related provisions. H.R. 3723, Viral Hepatitis Testing Act, regarding all provisions.
Food and Drug Administration Safety Over Sequestration Act of 2013
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.J. Res 59, Continuing Appropriations Resolution, regarding all biopharmaceutical related provisions. Labor, HHS Appropriations, regarding all biopharmaceutical related provisons. Agriculture approrpiations, regarding all biopharmceutical related provisions.H.R. 2725/S. 1413, FDA Safety over Sequestration Act, regarding all biopharmaceutical user-fees. No-bill, edcuational meetings regarding atrial fibrilation. No bill - regarding FDA regulatory issues and patent incentives related to the 21st Century Cures Initiative. Health Care Reform implementation - regarding essential health benefits coverage and all biopharmaceutical related provisions. H.R. 3723, Viral Hepatitis Testing Act, regarding all provisions.
Food and Drug Administration Safety Over Sequestration Act of 2013
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.J. Res 59, Continuing Appropriations Resolution, regarding all biopharmaceutical related provisions. Labor, HHS Appropriations, regarding all biopharmaceutical related provisons. Agriculture approrpiations, regarding all biopharmceutical related provisions.H.R. 2725/S. 1413, FDA Safety over Sequestration Act, regarding all biopharmaceutical user-fees. No-bill, educational meetings regarding atrial fibrillation. No bill - regarding FDA regulatory issues and patent incentives related to the 21st Century Cures Initiative. Health Care Reform implementation - regarding essential health benefits coverage and all biopharmaceutical related provisions. H.R. 3723, Viral Hepatitis Testing Act, regarding all provisions.
Protecting Seniors' Access to Medicare Act of 2013
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R. 1325 S. 323, "Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act" regarding all provisions. H.R. 1416, "Cancer Patient Protection Act of 2013," regarding all provisions. H.R. 351 and S. 351, "Protecting Seniors' Access to Medicare Act of 2013," regarding all provisions. H.R. 2010 and S. 1821, SGR Reform, regarding all provisions. H.R. 4301, Protecting Access to Medicare act, regarding all provisions.
Protecting Seniors' Access to Medicare Act of 2013
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R. 1325 S. 323, "Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act" regarding all provisions. H.R. 1416, "Cancer Patient Protection Act of 2013," regarding all provisions. H.R. 351 and S. 351, "Protecting Seniors' Access to Medicare Act of 2013," regarding all provisions. H.R. 2010 and S. 1821, SGR Reform, regarding all provisions.H.R. 4301, Protecting Access to Medicare act, regarding all provisions.
Protecting Seniors' Access to Medicare Act of 2013
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R. 1325 S. 323, "Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act" regarding all provsions. H.R. 1416, "Cancer Patient Protection Act of 2013," regarding all provisions. H.R. 351 and S. 351, "Protecting Seniors' Access to Medicare Act of 2013," regarding all provisions. H.R. 2010 an dS. 1821, SGR Reform, regarding all provisions.H.R. 4301, Protecting Access to Medicare act, regarding all provisions.
Protecting Seniors' Access to Medicare Act of 2013
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R. 1325 S. 323, "Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act" regarding all provisions. H.R. 1416, "Cancer Patient Protection Act of 2013," regarding all provisions. H.R. 351 and S. 351, "Protecting Seniors' Access to Medicare Act of 2013," regarding all provisions. H.R. 2010 and S. 1821, SGR Reform, regarding all provisions. H.R. 4301, Protecting Access to Medicare act, regarding all provisions.
Viral Hepatitis Testing Act of 2013
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.J. Res 59, Continuing Appropriations Resolution, regarding all biopharmaceutical related provisions. Labor, HHS Appropriations, regarding all biopharmaceutical related provisons. Agriculture approrpiations, regarding all biopharmceutical related provisions.H.R. 2725/S. 1413, FDA Safety over Sequestration Act, regarding all biopharmaceutical user-fees. No-bill, edcuational meetings regarding atrial fibrilation. No bill - regarding FDA regulatory issues and patent incentives related to the 21st Century Cures Initiative. Health Care Reform implementation - regarding essential health benefits coverage and all biopharmaceutical related provisions. H.R. 3723, Viral Hepatitis Testing Act, regarding all provisions.
Viral Hepatitis Testing Act of 2013
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.J. Res 59, Continuing Appropriations Resolution, regarding all biopharmaceutical related provisions. Labor, HHS Appropriations, regarding all biopharmaceutical related provisions. Agriculture appropriations, regarding all biopharmceutical related provisions. H.R. 2725/S. 1413, FDA Safety over Sequestration Act, regarding all biopharmaceutical user-fees. No-bill, educational meetings regarding atrial fibrillation. No bill - regarding FDA regulatory issues and patent incentives related to the 21st Century Cures Initiative. Health Care Reform implementation - regarding essential health benefits coverage and all biopharmaceutical related provisions. H.R. 3723, Viral Hepatitis Testing Act, regarding all provisions.
Viral Hepatitis Testing Act of 2013
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.J. Res 59, Continuing Appropriations Resolution, regarding all biopharmaceutical related provisions. Labor, HHS Appropriations, regarding all biopharmaceutical related provisions. Agriculture appropriations, regarding all biopharmceutical related provisions. H.R. 2725/S. 1413, FDA Safety over Sequestration Act, regarding all biopharmaceutical user-fees. No-bill, educational meetings regarding atrial fibrillation. No bill - regarding FDA regulatory issues and patent incentives related to the 21st Century Cures Initiative. Health Care Reform implementation - regarding essential health benefits coverage and all biopharmaceutical related provisions. H.R. 3723, Viral Hepatitis Testing Act, regarding all provisions.
Viral Hepatitis Testing Act of 2013
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.J. Res 59, Continuing Appropriations Resolution, regarding all biopharmaceutical related provisions. Labor, HHS Appropriations, regarding all biopharmaceutical related provisons. Agriculture approrpiations, regarding all biopharmceutical related provisions.H.R. 2725/S. 1413, FDA Safety over Sequestration Act, regarding all biopharmaceutical user-fees. No-bill, educational meetings regarding atrial fibrillation. No bill - regarding FDA regulatory issues and patent incentives related to the 21st Century Cures Initiative. Health Care Reform implementation - regarding essential health benefits coverage and all biopharmaceutical related provisions. H.R. 3723, Viral Hepatitis Testing Act, regarding all provisions.
Bipartisan Congressional Trade Priorities Act of 2014
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
No Bill, Trade and International Negotiation, regarding intellectual property rights in trade agreements and international negotiations. H.R. 3830 and S. 1900, Bipartisan Congressional Trade Priorities Act, regarding international intellectual property provisions.
Restoration of America's Wire Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R. 1325 S. 323, "Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act" regarding all provisions. H.R. 1416, "Cancer Patient Protection Act of 2013," regarding all provisions. H.R. 351 and S. 351, "Protecting Seniors' Access to Medicare Act of 2013," regarding all provisions. H.R. 2010 and S. 1821, SGR Reform, regarding all provisions.H.R. 4301, Protecting Access to Medicare act, regarding all provisions.
Restoration of America's Wire Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R. 1325 S. 323, "Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act" regarding all provsions. H.R. 1416, "Cancer Patient Protection Act of 2013," regarding all provisions. H.R. 351 and S. 351, "Protecting Seniors' Access to Medicare Act of 2013," regarding all provisions. H.R. 2010 an dS. 1821, SGR Reform, regarding all provisions.H.R. 4301, Protecting Access to Medicare act, regarding all provisions.
Restoration of America's Wire Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R. 1325 S. 323, "Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act" regarding all provisions. H.R. 1416, "Cancer Patient Protection Act of 2013," regarding all provisions. H.R. 351 and S. 351, "Protecting Seniors' Access to Medicare Act of 2013," regarding all provisions. H.R. 2010 and S. 1821, SGR Reform, regarding all provisions. H.R. 4301, Protecting Access to Medicare act, regarding all provisions.
Restoration of America's Wire Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R. 1325 S. 323, "Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act" regarding all provisions. H.R. 1416, "Cancer Patient Protection Act of 2013," regarding all provisions. H.R. 351 and S. 351, "Protecting Seniors' Access to Medicare Act of 2013," regarding all provisions. H.R. 2010 and S. 1821, SGR Reform, regarding all provisions. H.R. 4301, Protecting Access to Medicare act, regarding all provisions.
American Research and Competitiveness Act of 2014
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R. 3474, Tax Extenders legislation, regarding all biopharmaceutical related provisions. H.R. 4438, American Research and Investment Act, regarding all biopharmaceutical related provisions.
American Research and Competitiveness Act of 2014
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R. 3474, Tax Extenders legislation, regarding all biopharmaceutical related provisions. H.R. 4438, American Research and Investment Act, regarding all biopharmaceutical related provisions. H.R. 5771, to amend the Internal Revenue Code of 1986 to extend certain expiring provisions, including the research and development tax credit, regarding all biopharmaceutical related provisions.
American Research and Competitiveness Act of 2014
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R. 3474, Tax Extenders legislation, regarding all biopharmaceutical related provisions. H.R. 4438, American Research and Investment Act, regarding all biopharmaceutical related provisions. H.R. 5771, to amend the Internal Revenue Code of 1986 to extend certain expiring provisions, including the research and development tax credit, regarding all biopharmaceutical related provisions.
FDA User Fee Protection Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.J. Res 59, Continuing Appropriations Resolution, regarding all biopharmaceutical related provisions. Labor, HHS Appropriations, regarding all biopharmaceutical related provisions. Agriculture appropriations, regarding all biopharmceutical related provisions. H.R. 2725/S. 1413, FDA Safety over Sequestration Act, regarding all biopharmaceutical user-fees. No-bill, educational meetings regarding atrial fibrillation. No bill - regarding FDA regulatory issues and patent incentives related to the 21st Century Cures Initiative. Health Care Reform implementation - regarding essential health benefits coverage and all biopharmaceutical related provisions. H.R. 3723, Viral Hepatitis Testing Act, regarding all provisions.
FDA User Fee Protection Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.J. Res 59, Continuing Appropriations Resolution, regarding all biopharmaceutical related provisions. Labor, HHS Appropriations, regarding all biopharmaceutical related provisons. Agriculture approrpiations, regarding all biopharmceutical related provisions.H.R. 2725/S. 1413, FDA Safety over Sequestration Act, regarding all biopharmaceutical user-fees. No-bill, edcuational meetings regarding atrial fibrilation. No bill - regarding FDA regulatory issues and patent incentives related to the 21st Century Cures Initiative. Health Care Reform implementation - regarding essential health benefits coverage and all biopharmaceutical related provisions. H.R. 3723, Viral Hepatitis Testing Act, regarding all provisions.
FDA User Fee Protection Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.J. Res 59, Continuing Appropriations Resolution, regarding all biopharmaceutical related provisions. Labor, HHS Appropriations, regarding all biopharmaceutical related provisons. Agriculture approrpiations, regarding all biopharmceutical related provisions.H.R. 2725/S. 1413, FDA Safety over Sequestration Act, regarding all biopharmaceutical user-fees. No-bill, educational meetings regarding atrial fibrillation. No bill - regarding FDA regulatory issues and patent incentives related to the 21st Century Cures Initiative. Health Care Reform implementation - regarding essential health benefits coverage and all biopharmaceutical related provisions. H.R. 3723, Viral Hepatitis Testing Act, regarding all provisions.
FDA User Fee Protection Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.J. Res 59, Continuing Appropriations Resolution, regarding all biopharmaceutical related provisions. Labor, HHS Appropriations, regarding all biopharmaceutical related provisions. Agriculture appropriations, regarding all biopharmceutical related provisions. H.R. 2725/S. 1413, FDA Safety over Sequestration Act, regarding all biopharmaceutical user-fees. No-bill, educational meetings regarding atrial fibrillation. No bill - regarding FDA regulatory issues and patent incentives related to the 21st Century Cures Initiative. Health Care Reform implementation - regarding essential health benefits coverage and all biopharmaceutical related provisions. H.R. 3723, Viral Hepatitis Testing Act, regarding all provisions.
Philippines Charitable Giving Assistance Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R. 1325 S. 323, "Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act" regarding all provisions. H.R. 1416, "Cancer Patient Protection Act of 2013," regarding all provisions. H.R. 351 and S. 351, "Protecting Seniors' Access to Medicare Act of 2013," regarding all provisions. H.R. 2010 and S. 1821, SGR Reform, regarding all provisions.H.R. 4301, Protecting Access to Medicare act, regarding all provisions.
Philippines Charitable Giving Assistance Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R. 1325 S. 323, "Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act" regarding all provisions. H.R. 1416, "Cancer Patient Protection Act of 2013," regarding all provisions. H.R. 351 and S. 351, "Protecting Seniors' Access to Medicare Act of 2013," regarding all provisions. H.R. 2010 and S. 1821, SGR Reform, regarding all provisions. H.R. 4301, Protecting Access to Medicare act, regarding all provisions.
Philippines Charitable Giving Assistance Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R. 1325 S. 323, "Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act" regarding all provisions. H.R. 1416, "Cancer Patient Protection Act of 2013," regarding all provisions. H.R. 351 and S. 351, "Protecting Seniors' Access to Medicare Act of 2013," regarding all provisions. H.R. 2010 and S. 1821, SGR Reform, regarding all provisions. H.R. 4301, Protecting Access to Medicare act, regarding all provisions.
Bipartisan Congressional Trade Priorities Act of 2014
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
No Bill, Trade and International Negotiation, regarding intellectual property rights in trade agreements and international negotiations. H.R. 3830 and S. 1900, Bipartisan Congressional Trade Priorities Act, regarding international intellectual property provisions.
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2013
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R. 1325 S. 323, "Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act" regarding all provsions. H.R. 1416, "Cancer Patient Protection Act of 2013," regarding all provisions. H.R. 351 and S. 351, "Protecting Seniors' Access to Medicare Act of 2013," regarding all provisions. H.R. 2010 an dS. 1821, SGR Reform, regarding all provisions.H.R. 4301, Protecting Access to Medicare act, regarding all provisions.
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2013
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R. 1325 S. 323, "Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act" regarding all provisions. H.R. 1416, "Cancer Patient Protection Act of 2013," regarding all provisions. H.R. 351 and S. 351, "Protecting Seniors' Access to Medicare Act of 2013," regarding all provisions. H.R. 2010 and S. 1821, SGR Reform, regarding all provisions.H.R. 4301, Protecting Access to Medicare act, regarding all provisions.
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2013
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R. 1325 S. 323, "Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act" regarding all provisions. H.R. 1416, "Cancer Patient Protection Act of 2013," regarding all provisions. H.R. 351 and S. 351, "Protecting Seniors' Access to Medicare Act of 2013," regarding all provisions. H.R. 2010 and S. 1821, SGR Reform, regarding all provisions. H.R. 4301, Protecting Access to Medicare act, regarding all provisions.
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2013
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R. 1325 S. 323, "Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act" regarding all provisions. H.R. 1416, "Cancer Patient Protection Act of 2013," regarding all provisions. H.R. 351 and S. 351, "Protecting Seniors' Access to Medicare Act of 2013," regarding all provisions. H.R. 2010 and S. 1821, SGR Reform, regarding all provisions. H.R. 4301, Protecting Access to Medicare act, regarding all provisions.
Protecting Seniors' Access to Medicare Act of 2013
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R. 1325 S. 323, "Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act" regarding all provisions. H.R. 1416, "Cancer Patient Protection Act of 2013," regarding all provisions. H.R. 351 and S. 351, "Protecting Seniors' Access to Medicare Act of 2013," regarding all provisions. H.R. 2010 and S. 1821, SGR Reform, regarding all provisions. H.R. 4301, Protecting Access to Medicare act, regarding all provisions.
Protecting Seniors' Access to Medicare Act of 2013
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R. 1325 S. 323, "Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act" regarding all provsions. H.R. 1416, "Cancer Patient Protection Act of 2013," regarding all provisions. H.R. 351 and S. 351, "Protecting Seniors' Access to Medicare Act of 2013," regarding all provisions. H.R. 2010 an dS. 1821, SGR Reform, regarding all provisions.H.R. 4301, Protecting Access to Medicare act, regarding all provisions.
Protecting Seniors' Access to Medicare Act of 2013
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R. 1325 S. 323, "Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act" regarding all provisions. H.R. 1416, "Cancer Patient Protection Act of 2013," regarding all provisions. H.R. 351 and S. 351, "Protecting Seniors' Access to Medicare Act of 2013," regarding all provisions. H.R. 2010 and S. 1821, SGR Reform, regarding all provisions.H.R. 4301, Protecting Access to Medicare act, regarding all provisions.
Protecting Seniors' Access to Medicare Act of 2013
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R. 1325 S. 323, "Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act" regarding all provisions. H.R. 1416, "Cancer Patient Protection Act of 2013," regarding all provisions. H.R. 351 and S. 351, "Protecting Seniors' Access to Medicare Act of 2013," regarding all provisions. H.R. 2010 and S. 1821, SGR Reform, regarding all provisions. H.R. 4301, Protecting Access to Medicare act, regarding all provisions.
Proposing an amendment to the Constitution of the United States to protect the rights of crime victims.
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.J. Res 59, Continuing Appropriations Resolution, regarding all biopharmaceutical related provisions. Labor, HHS Appropriations, regarding all biopharmaceutical related provisons. Agriculture approrpiations, regarding all biopharmceutical related provisions.H.R. 2725/S. 1413, FDA Safety over Sequestration Act, regarding all biopharmaceutical user-fees. No-bill, educational meetings regarding atrial fibrillation. No bill - regarding FDA regulatory issues and patent incentives related to the 21st Century Cures Initiative. Health Care Reform implementation - regarding essential health benefits coverage and all biopharmaceutical related provisions. H.R. 3723, Viral Hepatitis Testing Act, regarding all provisions.
Proposing an amendment to the Constitution of the United States to protect the rights of crime victims.
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.J. Res 59, Continuing Appropriations Resolution, regarding all biopharmaceutical related provisions. Labor, HHS Appropriations, regarding all biopharmaceutical related provisons. Agriculture approrpiations, regarding all biopharmceutical related provisions.H.R. 2725/S. 1413, FDA Safety over Sequestration Act, regarding all biopharmaceutical user-fees. No-bill, edcuational meetings regarding atrial fibrilation. No bill - regarding FDA regulatory issues and patent incentives related to the 21st Century Cures Initiative. Health Care Reform implementation - regarding essential health benefits coverage and all biopharmaceutical related provisions. H.R. 3723, Viral Hepatitis Testing Act, regarding all provisions.
Proposing an amendment to the Constitution of the United States to protect the rights of crime victims.
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.J. Res 59, Continuing Appropriations Resolution, regarding all biopharmaceutical related provisions. Labor, HHS Appropriations, regarding all biopharmaceutical related provisions. Agriculture appropriations, regarding all biopharmceutical related provisions. H.R. 2725/S. 1413, FDA Safety over Sequestration Act, regarding all biopharmaceutical user-fees. No-bill, educational meetings regarding atrial fibrillation. No bill - regarding FDA regulatory issues and patent incentives related to the 21st Century Cures Initiative. Health Care Reform implementation - regarding essential health benefits coverage and all biopharmaceutical related provisions. H.R. 3723, Viral Hepatitis Testing Act, regarding all provisions.
Proposing an amendment to the Constitution of the United States to protect the rights of crime victims.
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.J. Res 59, Continuing Appropriations Resolution, regarding all biopharmaceutical related provisions. Labor, HHS Appropriations, regarding all biopharmaceutical related provisions. Agriculture appropriations, regarding all biopharmceutical related provisions. H.R. 2725/S. 1413, FDA Safety over Sequestration Act, regarding all biopharmaceutical user-fees. No-bill, educational meetings regarding atrial fibrillation. No bill - regarding FDA regulatory issues and patent incentives related to the 21st Century Cures Initiative. Health Care Reform implementation - regarding essential health benefits coverage and all biopharmaceutical related provisions. H.R. 3723, Viral Hepatitis Testing Act, regarding all provisions.
Establishing the budget for the United States Government for fiscal year 2014 and setting forth appropriate budgetary levels for fiscal years 2015 through 2023.
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
S.Con.Res.8 and H.Con. Res 25 concurrent resolutions setting forth the congressional budget for the United States Government for fiscal year 2014, revising the appropriate budgetary levels for fiscal year 2013, and setting forth the appropriate budgetary levels for fiscal years 2015 through 2023. Regarding Medicare and biopharmaceutical provisions.
Establishing the budget for the United States Government for fiscal year 2014 and setting forth appropriate budgetary levels for fiscal years 2015 through 2023.
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
S.CON.RES.8 and H.Con Res. 25, "Concurrent resolutions setting forth the Congressional Budget for the U. S. Government for Fiscal Year 2014," regarding Medicare.
Establishing the budget for the United States Government for fiscal year 2014 and setting forth appropriate budgetary levels for fiscal years 2015 through 2023.
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
S.CON.RES.8 and H. Con. Res 25 - Lobbied Members of Congress to oppose: extending Medicaid rebates to Part D; allowing for the importation of pharmaceuticals; and banning patent settlements between brand and generic drug manufacturers.
Establishing the budget for the United States Government for fiscal year 2014 and setting forth appropriate budgetary levels for fiscal years 2015 through 2023.
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
S.CON.RES.8 and H. CON.RES.25: Lobbied to oppose extending Medicaid rebates to Part D; allowing for the importation of pharmaceuticals and banning patent settlements between brand and generic drug manufacturers. Budget Control Act/Sequester: Lobbied to support appropriate reimbursement for Medicare Part B drugs.
National Diabetes Clinical Care Commission Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R. 933, Continuing Resolution Act of 2013 - Lobbied Members of Congress to: oppose extending Medicaid rebates to Part D; to increase access to HIV/AIDS Drugs in the AIDS Drug Assistance Program; and to prevent importation of prescription drugs. Labor, HHS Appropriations - Lobbied for increased access to HIV/AIDS drugs in the Aids Drug Assistance Program.Health Care Reform Implementation - Lobbied Members of Congress and the Administration to support open access to pharmaceuticals in the Essential Health Benefits Plan S.959/ H.R. 1919 Supply Chain legislation - Lobbied for passage of legislation to increase security of the drug distribution supply chain. Agriculture Appropriations - Lobbied to shield PDUFA user fees from sequestration from FY14 and beyond S. 539/H.R. 1074 - Lobbied for a public health approach to diabetes prevention and management No bill - Lobbied Members of Congress to raise awareness about Atrial Fibrillation and stroke prevention.
National Diabetes Clinical Care Commission Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H. J. Res 59, "Making continuing appropriations for fiscal year 2014, and for other purpose," regarding AIDS Drug Assistance Program, Medicare, and importation of prescription drugs.No bill - "Labor, HHS Appropriations," regarding the AIDS Drug Assistance Program. No bill - "Health Care Reform Implementation" - regarding Essential health benefits coverage. S.959/ H.R. 1919/ H.R. 3204 Drug Quality and Security Act, regarding all provisions. H.R. 2725/ S. 1413- "FDA Safety Over Sequestration Act," regarding all provisions. S. 539/H.R. 1074, "National Diabetes Clinical Care Commission Act," regarding all provisions. No bill - Raise awareness about Atrial Fibrillation and stroke prevention.
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2013
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R. 1325 and S. 323, "Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2013," regarding all provsions.H.R. 1416, "Cancer Patient Protection Act of 2013," regarding all provisions. H.R. 351 and S. 351, "Protecting Seniors' Access to Medicare Act of 2013," regarding all provisions.
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2013
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R. 1325 and S. 323, Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2013Lobbied for passage of legislation to remove cap on Medicare reimbursement of immunosuppressive therapy.H.R. 1416, Cancer Patient Protection Act of 2013 - Lobbied Members of Congress to support appropriate reimbursement for Medicare Part B drugs. Legislation to Repeal the Independent Payment Advisory Board - Lobbied for passage of bill to eliminate the Independent Payment Advisory Board
Cancer Patient Protection Act of 2013
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R. 1325 and S. 323, Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2013Lobbied for passage of legislation to remove cap on Medicare reimbursement of immunosuppressive therapy.H.R. 1416, Cancer Patient Protection Act of 2013 - Lobbied Members of Congress to support appropriate reimbursement for Medicare Part B drugs. Legislation to Repeal the Independent Payment Advisory Board - Lobbied for passage of bill to eliminate the Independent Payment Advisory Board
Cancer Patient Protection Act of 2013
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R. 1325 and S. 323, "Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2013," regarding all provsions.H.R. 1416, "Cancer Patient Protection Act of 2013," regarding all provisions. H.R. 351 and S. 351, "Protecting Seniors' Access to Medicare Act of 2013," regarding all provisions.
Safeguarding America's Pharmaceuticals Act of 2013
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H. J. Res 59, "Making continuing appropriations for fiscal year 2014, and for other purpose," regarding AIDS Drug Assistance Program, Medicare, and importation of prescription drugs.No bill - "Labor, HHS Appropriations," regarding the AIDS Drug Assistance Program. No bill - "Health Care Reform Implementation" - regarding Essential health benefits coverage. S.959/ H.R. 1919/ H.R. 3204 Drug Quality and Security Act, regarding all provisions. H.R. 2725/ S. 1413- "FDA Safety Over Sequestration Act," regarding all provisions. S. 539/H.R. 1074, "National Diabetes Clinical Care Commission Act," regarding all provisions. No bill - Raise awareness about Atrial Fibrillation and stroke prevention.
Safeguarding America's Pharmaceuticals Act of 2013
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R. 933, Continuing Resolution Act of 2013 - Lobbied Members of Congress to: oppose extending Medicaid rebates to Part D; to increase access to HIV/AIDS Drugs in the AIDS Drug Assistance Program; and to prevent importation of prescription drugs. Labor, HHS Appropriations - Lobbied for increased access to HIV/AIDS drugs in the Aids Drug Assistance Program.Health Care Reform Implementation - Lobbied Members of Congress and the Administration to support open access to pharmaceuticals in the Essential Health Benefits Plan S.959/ H.R. 1919 Supply Chain legislation - Lobbied for passage of legislation to increase security of the drug distribution supply chain. Agriculture Appropriations - Lobbied to shield PDUFA user fees from sequestration from FY14 and beyond S. 539/H.R. 1074 - Lobbied for a public health approach to diabetes prevention and management No bill - Lobbied Members of Congress to raise awareness about Atrial Fibrillation and stroke prevention.
Live by the Laws You Write Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R. 2010, S. 1821, legislation reforming Medicare's Sustainable Growth Rate, regarding all provisions.
Food and Drug Administration Safety Over Sequestration Act of 2013
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H. J. Res 59, "Making continuing appropriations for fiscal year 2014, and for other purpose," regarding AIDS Drug Assistance Program, Medicare, and importation of prescription drugs.No bill - "Labor, HHS Appropriations," regarding the AIDS Drug Assistance Program. No bill - "Health Care Reform Implementation" - regarding Essential health benefits coverage. S.959/ H.R. 1919/ H.R. 3204 Drug Quality and Security Act, regarding all provisions. H.R. 2725/ S. 1413- "FDA Safety Over Sequestration Act," regarding all provisions. S. 539/H.R. 1074, "National Diabetes Clinical Care Commission Act," regarding all provisions. No bill - Raise awareness about Atrial Fibrillation and stroke prevention.
Drug Quality and Security Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H. J. Res 59, "Making continuing appropriations for fiscal year 2014, and for other purpose," regarding AIDS Drug Assistance Program, Medicare, and importation of prescription drugs.No bill - "Labor, HHS Appropriations," regarding the AIDS Drug Assistance Program. No bill - "Health Care Reform Implementation" - regarding Essential health benefits coverage. S.959/ H.R. 1919/ H.R. 3204 Drug Quality and Security Act, regarding all provisions. H.R. 2725/ S. 1413- "FDA Safety Over Sequestration Act," regarding all provisions. S. 539/H.R. 1074, "National Diabetes Clinical Care Commission Act," regarding all provisions. No bill - Raise awareness about Atrial Fibrillation and stroke prevention.
Protecting Seniors' Access to Medicare Act of 2013
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R. 1325 and S. 323, "Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2013," regarding all provsions.H.R. 1416, "Cancer Patient Protection Act of 2013," regarding all provisions. H.R. 351 and S. 351, "Protecting Seniors' Access to Medicare Act of 2013," regarding all provisions.
Patent Abuse Reduction Act of 2013
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R. 3309, S. 1720, and S. 1612, S. 1013, S. 866, legislation to amend certain patent laws. Regarding all provisions.
FDA User Fee Protection Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H. J. Res 59, "Making continuing appropriations for fiscal year 2014, and for other purpose," regarding AIDS Drug Assistance Program, Medicare, and importation of prescription drugs.No bill - "Labor, HHS Appropriations," regarding the AIDS Drug Assistance Program. No bill - "Health Care Reform Implementation" - regarding Essential health benefits coverage. S.959/ H.R. 1919/ H.R. 3204 Drug Quality and Security Act, regarding all provisions. H.R. 2725/ S. 1413- "FDA Safety Over Sequestration Act," regarding all provisions. S. 539/H.R. 1074, "National Diabetes Clinical Care Commission Act," regarding all provisions. No bill - Raise awareness about Atrial Fibrillation and stroke prevention.
Patent Litigation Integrity Act of 2013
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R. 3309, S. 1720, and S. 1612, S. 1013, S. 866, legislation to amend certain patent laws. Regarding all provisions.
Patent Transparency and Improvements Act of 2013
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R. 3309, S. 1720, and S. 1612, S. 1013, S. 866, legislation to amend certain patent laws. Regarding all provisions.
Philippines Charitable Giving Assistance Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R. 2010, S. 1821, legislation reforming Medicare's Sustainable Growth Rate, regarding all provisions.
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2013
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R. 1325 and S. 323, Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2013Lobbied for passage of legislation to remove cap on Medicare reimbursement of immunosuppressive therapy.H.R. 1416, Cancer Patient Protection Act of 2013 - Lobbied Members of Congress to support appropriate reimbursement for Medicare Part B drugs. Legislation to Repeal the Independent Payment Advisory Board - Lobbied for passage of bill to eliminate the Independent Payment Advisory Board
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2013
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R. 1325 and S. 323, "Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2013," regarding all provsions.H.R. 1416, "Cancer Patient Protection Act of 2013," regarding all provisions. H.R. 351 and S. 351, "Protecting Seniors' Access to Medicare Act of 2013," regarding all provisions.
Protecting Seniors' Access to Medicare Act of 2013
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R. 1325 and S. 323, "Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2013," regarding all provsions.H.R. 1416, "Cancer Patient Protection Act of 2013," regarding all provisions. H.R. 351 and S. 351, "Protecting Seniors' Access to Medicare Act of 2013," regarding all provisions.
National Diabetes Clinical Care Commission Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H. J. Res 59, "Making continuing appropriations for fiscal year 2014, and for other purpose," regarding AIDS Drug Assistance Program, Medicare, and importation of prescription drugs.No bill - "Labor, HHS Appropriations," regarding the AIDS Drug Assistance Program. No bill - "Health Care Reform Implementation" - regarding Essential health benefits coverage. S.959/ H.R. 1919/ H.R. 3204 Drug Quality and Security Act, regarding all provisions. H.R. 2725/ S. 1413- "FDA Safety Over Sequestration Act," regarding all provisions. S. 539/H.R. 1074, "National Diabetes Clinical Care Commission Act," regarding all provisions. No bill - Raise awareness about Atrial Fibrillation and stroke prevention.
National Diabetes Clinical Care Commission Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R. 933, Continuing Resolution Act of 2013 - Lobbied Members of Congress to: oppose extending Medicaid rebates to Part D; to increase access to HIV/AIDS Drugs in the AIDS Drug Assistance Program; and to prevent importation of prescription drugs. Labor, HHS Appropriations - Lobbied for increased access to HIV/AIDS drugs in the Aids Drug Assistance Program.Health Care Reform Implementation - Lobbied Members of Congress and the Administration to support open access to pharmaceuticals in the Essential Health Benefits Plan S.959/ H.R. 1919 Supply Chain legislation - Lobbied for passage of legislation to increase security of the drug distribution supply chain. Agriculture Appropriations - Lobbied to shield PDUFA user fees from sequestration from FY14 and beyond S. 539/H.R. 1074 - Lobbied for a public health approach to diabetes prevention and management No bill - Lobbied Members of Congress to raise awareness about Atrial Fibrillation and stroke prevention.
Patent Quality Improvement Act of 2013
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R. 3309, S. 1720, and S. 1612, S. 1013, S. 866, legislation to amend certain patent laws. Regarding all provisions.
Pharmaceutical Quality, Security, and Accountability Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R. 933, Continuing Resolution Act of 2013 - Lobbied Members of Congress to: oppose extending Medicaid rebates to Part D; to increase access to HIV/AIDS Drugs in the AIDS Drug Assistance Program; and to prevent importation of prescription drugs. Labor, HHS Appropriations - Lobbied for increased access to HIV/AIDS drugs in the Aids Drug Assistance Program.Health Care Reform Implementation - Lobbied Members of Congress and the Administration to support open access to pharmaceuticals in the Essential Health Benefits Plan S.959/ H.R. 1919 Supply Chain legislation - Lobbied for passage of legislation to increase security of the drug distribution supply chain. Agriculture Appropriations - Lobbied to shield PDUFA user fees from sequestration from FY14 and beyond S. 539/H.R. 1074 - Lobbied for a public health approach to diabetes prevention and management No bill - Lobbied Members of Congress to raise awareness about Atrial Fibrillation and stroke prevention.
Pharmaceutical Quality, Security, and Accountability Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H. J. Res 59, "Making continuing appropriations for fiscal year 2014, and for other purpose," regarding AIDS Drug Assistance Program, Medicare, and importation of prescription drugs.No bill - "Labor, HHS Appropriations," regarding the AIDS Drug Assistance Program. No bill - "Health Care Reform Implementation" - regarding Essential health benefits coverage. S.959/ H.R. 1919/ H.R. 3204 Drug Quality and Security Act, regarding all provisions. H.R. 2725/ S. 1413- "FDA Safety Over Sequestration Act," regarding all provisions. S. 539/H.R. 1074, "National Diabetes Clinical Care Commission Act," regarding all provisions. No bill - Raise awareness about Atrial Fibrillation and stroke prevention.
A concurrent resolution expressing support for Children's Dental Health Month and honoring the memory of Deamonte Driver.
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
S.CON.RES.8 and H. CON.RES.25: Lobbied to oppose extending Medicaid rebates to Part D; allowing for the importation of pharmaceuticals and banning patent settlements between brand and generic drug manufacturers. Budget Control Act/Sequester: Lobbied to support appropriate reimbursement for Medicare Part B drugs.
A concurrent resolution expressing support for Children's Dental Health Month and honoring the memory of Deamonte Driver.
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
S.CON.RES.8 and H. Con. Res 25 - Lobbied Members of Congress to oppose: extending Medicaid rebates to Part D; allowing for the importation of pharmaceuticals; and banning patent settlements between brand and generic drug manufacturers.
Drug Safety Enhancement Act of 2011
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
S. 319, Pharmaceutical Market Access and Drug Safety Act - Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. S. 752, Lung Cancer Mortality Reduction Act of 2011 - Lobbied for passage of bill to reduce lung cancer mortality.NO BILL, Health Care Reform Implementation - Lobbied on implementation of provisions in the health care reform bill regarding biosimilars, the Independent Payment Advisory Board and the Annual Fee. S. 296 and H.R. 2245, Preserving Access to Life-Savings Medications Act - Lobbied to improve provisions in the drug shortage legislation. H.R. 1483, Drug Safety Enhancement Act of 2011 - Lobbied to pass meaningful drug safety legislation. S. 3187, the "Food and Drug Administration Safety and Innovation Act - Lobbied for passage of PDUFA legislation. S. 2113, Transforming the Regulatory Environment to Accelerate Access to Treatments - Lobbied to pass meaningful FDA reform legislation. S. 2236, Advancing Breakthrough Therapies for Patients Act of 2012 - Lobbied to pass meaningful FDA reform legislation. H.R. 4274, BCPA and PREA Reauthorization Act of 2012 - Lobbied for permanence of BCPA and PREA. H.R. 3497, MODERN Cures Act of 2011 - Lobbied for incentives for development of pharmacodiagnostics and dormant therapies. H.R. 3737, Unlocking Lifesaving Treatments for Rare-Diseases Act - Lobbied to pass meaningful FDA reform legislation. H.R. 4132, Faster Access to Specialized Treatments Act - Lobbied to pass meaningful FDA reform legislation. Labor, HHS Appropriations. Lobbied for increased access to HIV/AIDS drugs in the AIDS Drug Assistance Program.
Drug Safety Enhancement Act of 2011
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
S. 319, Pharmaceutical Market Access and Drug Safety Act - Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. S. 752, Lung Cancer Mortality Reduction Act of 2011 - Lobbied for passage of bill to reduce lung cancer mortality. NO BILL, Health Care Reform Implementation - Lobbied on implementation of provisions in the health care reform bill regarding biosimilars, the Independent Payment Advisory Board and the Annual Fee. S. 296 and H.R. 2245, Preserving Access to Life-Savings Medications Act - Lobbied to improve provisions in the drug shortage legislation. H.R. 1483, Drug Safety Enhancement Act of 2011 - Lobbied to pass meaningful drug safety legislation. S. 3187, the "Food and Drug Administration Safety and Innovation Act - Lobbied for passage of PDUFA legislation. Labor, HHS Appropriations - Lobbied for increased access to HIV/AIDS drugs in the AIDS Drug Assistance Program. S. 2113, Transforming the Regulatory Environment to Accelerate Access to Treatments - Lobbied to pass meaningful FDA reform legislation. S. 2236, Advancing Breakthrough Therapies for Patients Act of 2012 - Lobbied to pass meaningful FDA reform legislation. H.R. 4274, BCPA and PREA Reauthorization Act of 2012 - Lobbied for permanence of BCPA and PREA. H.R. 3497, MODERN Cures Act of 2011 - Lobbied for incentives for development of pharmacodiagnostics and dormant therapies. H.R. 3737, Unlocking Lifesaving Treatments for Rare-Diseases Act - Lobbied to pass meaningful FDA reform legislation. H.R. 4132, Faster Access to Specialized Treatments Act - Lobbied to pass meaningful FDA reform legislation.
Drug Safety Enhancement Act of 2011
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
S. 319, Pharmaceutical Market Access and Drug Safety Act - Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. S. 752, Lung Cancer Mortality Reduction Act of 2011 - Lobbied for passage of bill to reduce lung cancer mortality. NO BILL, Health Care Reform Implementation - Lobbied on implementation of provisions in the health care reform bill regarding biosimilars, the Independent Payment Advisory Board and the Annual Fee. S. 296 and H.R. 2245, Preserving Access to Life-Savings Medications Act - Lobbied to improve provisions in the drug shortage legislation. H.R. 1483, Drug Safety Enhancement Act of 2011 - Lobbied to pass meaningful drug safety legislation. S. 3187, the "Food and Drug Administration Safety and Innovation Act - Lobbied for passage of PDUFA legislation. S. 2113, Transforming the Regulatory Environment to Accelerate Access to Treatments - Lobbied to pass meaningful FDA reform legislation. S. 2236, Advancing Breakthrough Therapies for Patients Act of 2012 - Lobbied to pass meaningful FDA reform legislation. H.R. 4274, BCPA and PREA Reauthorization Act of 2012 - Lobbied for permanence of BCPA and PREA. H.R. 3497, MODERN Cures Act of 2011 - Lobbied for incentives for development of pharmacodiagnostics and dormant therapies. H.R. 3737, Unlocking Lifesaving Treatments for Rare-Diseases Act - Lobbied to pass meaningful FDA reform legislation. H.R. 4132, Faster Access to Specialized Treatments Act - Lobbied to pass meaningful FDA reform legislation. Labor, HHS Appropriations. Lobbied for increased access to HIV/AIDS drugs in the AIDS Drug Assistance Program. NO BILL, Supply chain draft legislation - Lobbied for passage of legisaltion to increase security of the drug distribution supply chain.
Drug Safety Enhancement Act of 2011
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
S. 319, Pharmaceutical Market Access and Drug Safety Act - Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. S. 752, Lung Cancer Mortality Reduction Act of 2011 - Lobbied for passage of bill to reduce lung cancer mortality. NO BILL, Health Care Reform Implementation - Lobbied on implementation of provisions in the health care reform bill regarding biosimilars, the Independent Payment Advisory Board and the Annual Fee. S. 296 and H.R. 2245, Preserving Access to Life-Savings Medications Act - Lobbied to improve provisions in the drug shortage legislation. H.R. 1483, Drug Safety Enhancement Act of 2011 - Lobbied to pass meaningful drug safety legislation. NO BILL, Reauthorization of the Prescription Drug User Fee Act - Lobbied for passage of clean PDUFA legislation. Labor, HHS Appropriations - Lobbied for increased access to HIV/AIDS drugs in the AIDS Drug Assistance Program. S. 2113, Transforming the Regulatory Environment to Accelerate Access to Treatments - Lobbied to pass meaningful FDA reform legislation. S. 2236, Advancing Breakthrough Therapies for Patients Act of 2012 - Lobbied to pass meaningful FDA reform legislation. H.R. 4274, BCPA and PREA Reauthorization Act of 2012 - Lobbied for permanence of BCPA and PREA. H.R. 3497, MODERN Cures Act of 2011 - Lobbied for incentives for development of pharmacodiagnostics and dormant therapies. H.R. 3737, Unlocking Lifesaving Treatments for Rare-Diseases Act - Lobbied to pass meaningful FDA reform legislation. H.R. 4132, Faster Access to Specialized Treatments Act - Lobbied to pass meaningful FDA reform legislation.
Drug Safety Enhancement Act of 2011
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
S. 319, Pharmaceutical Market Access and Drug Safety Act - Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. S. 752, Lung Cancer Mortality Reduction Act of 2011 - Lobbied for passage of bill to reduce lung cancer mortality. NO BILL, Health Care Reform Implementation - Lobbied on implementation of provisions in the health care reform bill regarding biosimilars, the Independent Payment Advisory Board and the Annual Fee. S. 296 and H.R. 2245, Preserving Access to Life-Savings Medications Act - Lobbied to improve provisions in the drug shortage legislation. H.R. 1483, Drug Safety Enhancement Act of 2011 - Lobbied to pass meaningful drug safety legislation. NO BILL, Reauthorization of the Prescription Drug User Fee Act - Lobbied for passage of clean PDUFA legislation. Labor, HHS Appropriations - Lobbied for increased access to HIV/AIDS drugs in the AIDS Drug Assistance Program. S. 2113, Transforming the Regulatory Environment to Accelerate Access to Treatments - Lobbied to pass meaningful FDA reform legislation. S. 2236, Advancing Breakthrough Therapies for Patients Act of 2012 - Lobbied to pass meaningful FDA reform legislation. H.R. 4274, BCPA and PREA Reauthorization Act of 2012 - Lobbied for permanence of BCPA and PREA. H.R. 3497, MODERN Cures Act of 2011 - Lobbied for incentives for development of pharmacodiagnostics and dormant therapies. H.R. 3737, Unlocking Lifesaving Treatments for Rare-Diseases Act - Lobbied to pass meaningful FDA reform legislation. H.R. 4132, Faster Access to Specialized Treatments Act - Lobbied to pass meaningful FDA reform legislation.
Drug Safety Enhancement Act of 2011
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
S. 319, Pharmaceutical Market Access and Drug Safety Act - Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. S. 752, Lung Cancer Mortality Reduction Act of 2011 - Lobbied for passage of bill to reduce lung cancer mortality. NO BILL, Health Care Reform Implementation - Lobbied on implementation of provisions in the health care reform bill regarding biosimilars, the Independent Payment Advisory Board and the Annual Fee. S. 296 and H.R. 2245, Preserving Access to Life-Savings Medications Act - Lobbied to improve provisions in the drug shortage legislation. H.R. 1483, Drug Safety Enhancement Act of 2011 - Lobbied to pass meaningful drug safety legislation. S. 3187, the "Food and Drug Administration Safety and Innovation Act - Lobbied for passage of PDUFA legislation. S. 2113, Transforming the Regulatory Environment to Accelerate Access to Treatments - Lobbied to pass meaningful FDA reform legislation. S. 2236, Advancing Breakthrough Therapies for Patients Act of 2012 - Lobbied to pass meaningful FDA reform legislation. H.R. 4274, BCPA and PREA Reauthorization Act of 2012 - Lobbied for permanence of BCPA and PREA. H.R. 3497, MODERN Cures Act of 2011 - Lobbied for incentives for development of pharmacodiagnostics and dormant therapies. H.R. 3737, Unlocking Lifesaving Treatments for Rare-Diseases Act - Lobbied to pass meaningful FDA reform legislation. H.R. 4132, Faster Access to Specialized Treatments Act - Lobbied to pass meaningful FDA reform legislation. Labor, HHS Appropriations. Lobbied for increased access to HIV/AIDS drugs in the AIDS Drug Assistance Program.
Drug Safety Enhancement Act of 2011
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
S. 319, Pharmaceutical Market Access and Drug Safety Act - Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. S. 752, Lung Cancer Mortality Reduction Act of 2011 - Lobbied for passage of bill to reduce lung cancer mortality. NO BILL, Health Care Reform Implementation - Lobbied on implementation of provisions in the health care reform bill regarding biosimilars, the Independent Payment Advisory Board and the Annual Fee. S. 296 and H.R. 2245, Preserving Access to Life-Savings Medications Act - Lobbied to improve provisions in the drug shortage legislation. H.R. 1483, Drug Safety Enhancement Act of 2011 - Lobbied to pass meaningful drug safety legislation. NO BILL, Reauthorization of the Prescription Drug User Fee Act - Lobbied for passage of clean PDUFA legislation. Labor, HHS Appropriations - Lobbied for increased access to HIV/AIDS drugs in the AIDS Drug Assistance Program. S. 2113, Transforming the Regulatory Environment to Accelerate Access to Treatments - Lobbied to pass meaningful FDA reform legislation. S. 2236, Advancing Breakthrough Therapies for Patients Act of 2012 - Lobbied to pass meaningful FDA reform legislation. H.R. 4274, BCPA and PREA Reauthorization Act of 2012 - Lobbied for permanence of BCPA and PREA. H.R. 3497, MODERN Cures Act of 2011 - Lobbied for incentives for development of pharmacodiagnostics and dormant therapies. H.R. 3737, Unlocking Lifesaving Treatments for Rare-Diseases Act - Lobbied to pass meaningful FDA reform legislation. H.R. 4132, Faster Access to Specialized Treatments Act - Lobbied to pass meaningful FDA reform legislation.
Medicare Drug Savings Act of 2011
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
S. 668, Health Care Bureaucrats Elimination Act - Lobbied for passage of bill to eliminate the Independent Payment Advisory Board. H.R. 452, Medicare Decisions Accountability Act - Lobbied for passage of bill to eliminate the Independent Payment Advisory Board. Bill not yet introduced, The Medicare Home Infusion Therapy Coverage Act - Lobbied for expanded coverage of home infusion therapy. S. 1454 and H.R. 2969, Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act - Lobbied for extended coverage of immunosuppresive drugs in Medicare. H.R. 2190 and S. 1206, Medicare Drug Savings Act of 2011 - Lobbied to oppose extending Medicaid rebates to Medicare Part D.
2015 · second_quarter · Q2
Labor, HHS Appropriations,regarding all biopharmaceutical related provisions. Agriculture Appropriations, regarding all biopharmaceutical related provisions. H.R. 1078, FDA Safety Over Sequestration Act, regarding all biopharmaceutical related provisions. No bill, raised awareness about atrial fibrillation and stroke prevention. H/R. 1101, Viral Hepatitis Testing Act, regarding all biopharmaceutical related provisions. H.R.6, 21st Century Cures Initiative, regarding all biopharmaceutical related provisions.
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2015 · first_quarter · Q1
H.R. 1416, Cancer Patient Protection Act, regarding all biopharmaceutical related provisions. H.R. 1190 and S. 41, Protecting Seniors' Access to Medicare Act, regarding all biopharmaceutical related provisions. H.R. 2, Medicare Access and CHIP Authorization Act, regarding all biopharmaceutical related provisions
Labor, HHS Appropriations,regarding all biopharmaceutical related provisions. Agriculture Appropriations, regarding all biopharmaceutical related provisions. H.R. 1078, FDA Safety Over Sequestration Act, regarding all biopharmaceutical related provisions. No bill, raised awareness about atrial fibrillation and stroke prevention. H/R. 1101, Viral Hepatitis Testing Act, regarding all biopharmaceutical related provisions. No bill, 21st Century Cures Initiative, regarding all biopharmaceutical related provisions.
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2014 · fourth_quarter · 4A
H.R. 1325 S. 323, "Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act" regarding all provisions. H.R. 1416, "Cancer Patient Protection Act of 2013," regarding all provisions. H.R. 351 and S. 351, "Protecting Seniors' Access to Medicare Act of 2013," regarding all provisions. H.R. 2010 and S. 1821, SGR Reform, regarding all provisions. H.R. 4301, Protecting Access to Medicare act, regarding all provisions.
H.R. 3474, Tax Extenders legislation, regarding all biopharmaceutical related provisions. H.R. 4438, American Research and Investment Act, regarding all biopharmaceutical related provisions. H.R. 5771, to amend the Internal Revenue Code of 1986 to extend certain expiring provisions, including the research and development tax credit, regarding all biopharmaceutical related provisions.
H.J. Res 59, Continuing Appropriations Resolution, regarding all biopharmaceutical related provisions. Labor, HHS Appropriations, regarding all biopharmaceutical related provisions. Agriculture appropriations, regarding all biopharmceutical related provisions. H.R. 2725/S. 1413, FDA Safety over Sequestration Act, regarding all biopharmaceutical user-fees. No-bill, educational meetings regarding atrial fibrillation. No bill - regarding FDA regulatory issues and patent incentives related to the 21st Century Cures Initiative. Health Care Reform implementation - regarding essential health benefits coverage and all biopharmaceutical related provisions. H.R. 3723, Viral Hepatitis Testing Act, regarding all provisions.
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2014 · fourth_quarter · Q4
H.R. 1325 S. 323, "Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act" regarding all provisions. H.R. 1416, "Cancer Patient Protection Act of 2013," regarding all provisions. H.R. 351 and S. 351, "Protecting Seniors' Access to Medicare Act of 2013," regarding all provisions. H.R. 2010 and S. 1821, SGR Reform, regarding all provisions. H.R. 4301, Protecting Access to Medicare act, regarding all provisions.
H.J. Res 59, Continuing Appropriations Resolution, regarding all biopharmaceutical related provisions. Labor, HHS Appropriations, regarding all biopharmaceutical related provisions. Agriculture appropriations, regarding all biopharmceutical related provisions. H.R. 2725/S. 1413, FDA Safety over Sequestration Act, regarding all biopharmaceutical user-fees. No-bill, educational meetings regarding atrial fibrillation. No bill - regarding FDA regulatory issues and patent incentives related to the 21st Century Cures Initiative. Health Care Reform implementation - regarding essential health benefits coverage and all biopharmaceutical related provisions. H.R. 3723, Viral Hepatitis Testing Act, regarding all provisions.
H.R. 3474, Tax Extenders legislation, regarding all biopharmaceutical related provisions. H.R. 4438, American Research and Investment Act, regarding all biopharmaceutical related provisions. H.R. 5771, to amend the Internal Revenue Code of 1986 to extend certain expiring provisions, including the research and development tax credit, regarding all biopharmaceutical related provisions.
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2014 · third_quarter · Q3
H.R. 3474, Tax Extenders legislation, regarding all biopharmaceutical related provisions. H.R. 4438, American Research and Investment Act, regarding all biopharmaceutical related provisions.
H.R. 1325 S. 323, "Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act" regarding all provisions. H.R. 1416, "Cancer Patient Protection Act of 2013," regarding all provisions. H.R. 351 and S. 351, "Protecting Seniors' Access to Medicare Act of 2013," regarding all provisions. H.R. 2010 and S. 1821, SGR Reform, regarding all provisions.H.R. 4301, Protecting Access to Medicare act, regarding all provisions.
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2014 · second_quarter · Q2
H.R. 1325 S. 323, "Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act" regarding all provsions. H.R. 1416, "Cancer Patient Protection Act of 2013," regarding all provisions. H.R. 351 and S. 351, "Protecting Seniors' Access to Medicare Act of 2013," regarding all provisions. H.R. 2010 an dS. 1821, SGR Reform, regarding all provisions.H.R. 4301, Protecting Access to Medicare act, regarding all provisions.
H.J. Res 59, Continuing Appropriations Resolution, regarding all biopharmaceutical related provisions. Labor, HHS Appropriations, regarding all biopharmaceutical related provisons. Agriculture approrpiations, regarding all biopharmceutical related provisions.H.R. 2725/S. 1413, FDA Safety over Sequestration Act, regarding all biopharmaceutical user-fees. No-bill, edcuational meetings regarding atrial fibrilation. No bill - regarding FDA regulatory issues and patent incentives related to the 21st Century Cures Initiative. Health Care Reform implementation - regarding essential health benefits coverage and all biopharmaceutical related provisions. H.R. 3723, Viral Hepatitis Testing Act, regarding all provisions.
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2014 · first_quarter · Q1
No Bill, Trade and International Negotiation, regarding intellectual property rights in trade agreements and international negotiations. H.R. 3830 and S. 1900, Bipartisan Congressional Trade Priorities Act, regarding international intellectual property provisions.
No bill - "Health Care Reform Implementation" - regarding Essential health benefits coverage. No bill - Raise awareness about Atrial Fibrillation and stroke prevention.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2013 · fourth_quarter · Q4
S.Con.Res.8 and H.Con. Res 25 concurrent resolutions setting forth the congressional budget for the United States Government for fiscal year 2014, revising the appropriate budgetary levels for fiscal year 2013, and setting forth the appropriate budgetary levels for fiscal years 2015 through 2023. Regarding Medicare and biopharmaceutical provisions.
H.R. 3309, S. 1720, and S. 1612, S. 1013, S. 866, legislation to amend certain patent laws. Regarding all provisions.
H. J. Res 59, "Making continuing appropriations for fiscal year 2014, and for other purpose," regarding AIDS Drug Assistance Program, Medicare, and importation of prescription drugs.
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2013 · third_quarter · Q3
S.CON.RES.8 and H.Con Res. 25, "Concurrent resolutions setting forth the Congressional Budget for the U. S. Government for Fiscal Year 2014," regarding Medicare.
No Bill, Trade and International Negotiation, regarding intellectual property rights in trade agreements and international negotiations.
H. J. Res 59, "Making continuing appropriations for fiscal year 2014, and for other purpose," regarding AIDS Drug Assistance Program, Medicare, and importation of prescription drugs.No bill - "Labor, HHS Appropriations," regarding the AIDS Drug Assistance Program. No bill - "Health Care Reform Implementation" - regarding Essential health benefits coverage. S.959/ H.R. 1919/ H.R. 3204 Drug Quality and Security Act, regarding all provisions. H.R. 2725/ S. 1413- "FDA Safety Over Sequestration Act," regarding all provisions. S. 539/H.R. 1074, "National Diabetes Clinical Care Commission Act," regarding all provisions. No bill - Raise awareness about Atrial Fibrillation and stroke prevention.
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2013 · second_quarter · Q2
H.R. 933, Continuing Resolution Act of 2013 - Lobbied Members of Congress to: oppose extending Medicaid rebates to Part D; to increase access to HIV/AIDS Drugs in the AIDS Drug Assistance Program; and to prevent importation of prescription drugs. Labor, HHS Appropriations - Lobbied for increased access to HIV/AIDS drugs in the Aids Drug Assistance Program.Health Care Reform Implementation - Lobbied Members of Congress and the Administration to support open access to pharmaceuticals in the Essential Health Benefits Plan S.959/ H.R. 1919 Supply Chain legislation - Lobbied for passage of legislation to increase security of the drug distribution supply chain. Agriculture Appropriations - Lobbied to shield PDUFA user fees from sequestration from FY14 and beyond S. 539/H.R. 1074 - Lobbied for a public health approach to diabetes prevention and management No bill - Lobbied Members of Congress to raise awareness about Atrial Fibrillation and stroke prevention.
H.R. 1325 and S. 323, Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2013Lobbied for passage of legislation to remove cap on Medicare reimbursement of immunosuppressive therapy.H.R. 1416, Cancer Patient Protection Act of 2013 - Lobbied Members of Congress to support appropriate reimbursement for Medicare Part B drugs. Legislation to Repeal the Independent Payment Advisory Board - Lobbied for passage of bill to eliminate the Independent Payment Advisory Board
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2013 · first_quarter · Q1
Legislation to Repeal the Independent Payment Advisory Board: Lobbied for passage of bill to eliminate the Independent Payment Advisory Board.
H.R. 933, Continuing Resolution Act of 2013: Lobbied to oppose extending Medicaid rebates to Part D; to increase access to HIV/AIDS drugs in the AIDS Drug Assistance Program, and to prevent importation of prescription drugs. Labor, HHS Appropriations: Lobbied for increased access to HIV/AIDS drugs in the Aids Drugs Assistance Program.Health Care Reform Implementation: Lobbied to support open access to pharmaceuticals in the Essential Health Benefits Plan. NO BILL: Supply Chain Draft Legislation: Lobbied for passage of legislation to increase security of the drug distribution supply chain.
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2012 · third_quarter · 3A
S. 668, Health Care Bureaucrats Elimination Act - Lobbied for passage of bill to eliminate the Independent Payment Advisory Board. H.R. 452, Medicare Decisions Accountability Act - Lobbied for passage of bill to eliminate the Independent Payment Advisory Board.Bill not yet introduced, The Medicare Home Infusion Therapy Coverage Act - Lobbied for expanded coverage of home infusion therapy. S. 1454 and H.R. 2969, Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act - Lobbied for extended coverage of immunosuppresive drugs in Medicare. H.R. 2190 and S. 1206, Medicare Drug Savings Act of 2011 - Lobbied to oppose extending Medicaid rebates to Medicare Part D. No Bill, Health care reform implementation. Lobbied CMS on new definition of the Average Manufacturer's Price calculation in Medicaid.
S. 319, Pharmaceutical Market Access and Drug Safety Act - Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. S. 752, Lung Cancer Mortality Reduction Act of 2011 - Lobbied for passage of bill to reduce lung cancer mortality.NO BILL, Health Care Reform Implementation - Lobbied on implementation of provisions in the health care reform bill regarding biosimilars, the Independent Payment Advisory Board and the Annual Fee. S. 296 and H.R. 2245, Preserving Access to Life-Savings Medications Act - Lobbied to improve provisions in the drug shortage legislation. H.R. 1483, Drug Safety Enhancement Act of 2011 - Lobbied to pass meaningful drug safety legislation. S. 3187, the "Food and Drug Administration Safety and Innovation Act - Lobbied for passage of PDUFA legislation. S. 2113, Transforming the Regulatory Environment to Accelerate Access to Treatments - Lobbied to pass meaningful FDA reform legislation. S. 2236, Advancing Breakthrough Therapies for Patients Act of 2012 - Lobbied to pass meaningful FDA reform legislation. H.R. 4274, BCPA and PREA Reauthorization Act of 2012 - Lobbied for permanence of BCPA and PREA. H.R. 3497, MODERN Cures Act of 2011 - Lobbied for incentives for development of pharmacodiagnostics and dormant therapies. H.R. 3737, Unlocking Lifesaving Treatments for Rare-Diseases Act - Lobbied to pass meaningful FDA reform legislation. H.R. 4132, Faster Access to Specialized Treatments Act - Lobbied to pass meaningful FDA reform legislation. Labor, HHS Appropriations. Lobbied for increased access to HIV/AIDS drugs in the AIDS Drug Assistance Program.
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2012 · fourth_quarter · Q4
H.R. 2055, Consolidated Appropriations Act of 2011 - Lobbied to oppose extending Medicaid rebates to Medicare Part D. Agriculture, Rural Development, FDA and Related Agencies Appropriations Act of 2012 - Lobbied against potential amendments to allow for the importation of unsafe prescription drugs. H.R. 8, The American Tax Payers Relief Act - Lobbied for passage of the R&E Tax Credit and against amendments that reduce access to pharmaceuticals.
S. 668, Health Care Bureaucrats Elimination Act - Lobbied for passage of bill to eliminate the Independent Payment Advisory Board. H.R. 452, Medicare Decisions Accountability Act - Lobbied for passage of bill to eliminate the Independent Payment Advisory Board. Bill not yet introduced, The Medicare Home Infusion Therapy Coverage Act - Lobbied for expanded coverage of home infusion therapy. S. 1454 and H.R. 2969, Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act - Lobbied for extended coverage of immunosuppresive drugs in Medicare. H.R. 2190 and S. 1206, Medicare Drug Savings Act of 2011 - Lobbied to oppose extending Medicaid rebates to Medicare Part D. No Bill, Health care reform implementation. Lobbied CMS on new definition of the Average Manufacturer's Price calculation in Medicaid.
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2012 · third_quarter · Q3
H.R. 2055, Consolidated Appropriations Act of 2011 - Lobbied to oppose extending Medicaid rebates to Medicare Part D. Agriculture, Rural Development, FDA and Related Agencies Appropriations Act of 2012 - Lobbied against potential amendments to allow for the importation of unsafe prescription drugs.
S. 668, Health Care Bureaucrats Elimination Act - Lobbied for passage of bill to eliminate the Independent Payment Advisory Board. H.R. 452, Medicare Decisions Accountability Act - Lobbied for passage of bill to eliminate the Independent Payment Advisory Board. Bill not yet introduced, The Medicare Home Infusion Therapy Coverage Act - Lobbied for expanded coverage of home infusion therapy. S. 1454 and H.R. 2969, Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act - Lobbied for extended coverage of immunosuppresive drugs in Medicare. H.R. 2190 and S. 1206, Medicare Drug Savings Act of 2011 - Lobbied to oppose extending Medicaid rebates to Medicare Part D. No Bill, Health care reform implementation. Lobbied CMS on new definition of the Average Manufacturer's Price calculation in Medicaid.
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2012 · first_quarter · 1A
S. 319, Pharmaceutical Market Access and Drug Safety Act - Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. S. 752, Lung Cancer Mortality Reduction Act of 2011 - Lobbied for passage of bill to reduce lung cancer mortality. NO BILL, Health Care Reform Implementation - Lobbied on implementation of provisions in the health care reform bill regarding biosimilars, the Independent Payment Advisory Board and the Annual Fee. S. 296 and H.R. 2245, Preserving Access to Life-Savings Medications Act - Lobbied to improve provisions in the drug shortage legislation. H.R. 1483, Drug Safety Enhancement Act of 2011 - Lobbied to pass meaningful drug safety legislation. NO BILL, Reauthorization of the Prescription Drug User Fee Act - Lobbied for passage of clean PDUFA legislation. Labor, HHS Appropriations - Lobbied for increased access to HIV/AIDS drugs in the AIDS Drug Assistance Program. S. 2113, Transforming the Regulatory Environment to Accelerate Access to Treatments - Lobbied to pass meaningful FDA reform legislation. S. 2236, Advancing Breakthrough Therapies for Patients Act of 2012 - Lobbied to pass meaningful FDA reform legislation. H.R. 4274, BCPA and PREA Reauthorization Act of 2012 - Lobbied for permanence of BCPA and PREA. H.R. 3497, MODERN Cures Act of 2011 - Lobbied for incentives for development of pharmacodiagnostics and dormant therapies. H.R. 3737, Unlocking Lifesaving Treatments for Rare-Diseases Act - Lobbied to pass meaningful FDA reform legislation. H.R. 4132, Faster Access to Specialized Treatments Act - Lobbied to pass meaningful FDA reform legislation.
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2012 · second_quarter · Q2
S. 668, Health Care Bureaucrats Elimination Act - Lobbied for passage of bill to eliminate the Independent Payment Advisory Board. H.R. 452, Medicare Decisions Accountability Act - Lobbied for passage of bill to eliminate the Independent Payment Advisory Board. Bill not yet introduced, The Medicare Home Infusion Therapy Coverage Act - Lobbied for expanded coverage of home infusion therapy. S. 1454 and H.R. 2969, Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act - Lobbied for extended coverage of immunosuppresive drugs in Medicare. H.R. 2190 and S. 1206, Medicare Drug Savings Act of 2011 - Lobbied to oppose extending Medicaid rebates to Medicare Part D.
S. 319, Pharmaceutical Market Access and Drug Safety Act - Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. S. 752, Lung Cancer Mortality Reduction Act of 2011 - Lobbied for passage of bill to reduce lung cancer mortality. NO BILL, Health Care Reform Implementation - Lobbied on implementation of provisions in the health care reform bill regarding biosimilars, the Independent Payment Advisory Board and the Annual Fee. S. 296 and H.R. 2245, Preserving Access to Life-Savings Medications Act - Lobbied to improve provisions in the drug shortage legislation. H.R. 1483, Drug Safety Enhancement Act of 2011 - Lobbied to pass meaningful drug safety legislation. S. 3187, the "Food and Drug Administration Safety and Innovation Act - Lobbied for passage of PDUFA legislation. Labor, HHS Appropriations - Lobbied for increased access to HIV/AIDS drugs in the AIDS Drug Assistance Program. S. 2113, Transforming the Regulatory Environment to Accelerate Access to Treatments - Lobbied to pass meaningful FDA reform legislation. S. 2236, Advancing Breakthrough Therapies for Patients Act of 2012 - Lobbied to pass meaningful FDA reform legislation. H.R. 4274, BCPA and PREA Reauthorization Act of 2012 - Lobbied for permanence of BCPA and PREA. H.R. 3497, MODERN Cures Act of 2011 - Lobbied for incentives for development of pharmacodiagnostics and dormant therapies. H.R. 3737, Unlocking Lifesaving Treatments for Rare-Diseases Act - Lobbied to pass meaningful FDA reform legislation. H.R. 4132, Faster Access to Specialized Treatments Act - Lobbied to pass meaningful FDA reform legislation.
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2012 · first_quarter · Q1
H.R. 2055, Consolidated Appropriations Act of 2011 - Lobbied to oppose extending Medicaid rebates to Medicare Part D. Agriculture, Rural Development, FDA and Related Agencies Appropriations Act of 2012 - Lobbied against potential amendments to allow for the importation of unsafe prescription drugs.
S. 668, Health Care Bureaucrats Elimination Act - Lobbied for passage of bill to eliminate the Independent Payment Advisory Board. H.R. 452, Medicare Decisions Accountability Act - Lobbied for passage of bill to eliminate the Independent Payment Advisory Board. Bill not yet introduced, The Medicare Home Infusion Therapy Coverage Act - Lobbied for expanded coverage of home infusion therapy. S. 1454 and H.R. 2969, Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act - Lobbied for extended coverage of immunosuppresive drugs in Medicare. H.R. 2190 and S. 1206, Medicare Drug Savings Act of 2011 - Lobbied to oppose extending Medicaid rebates to Medicare Part D.
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2012 · first_quarter · Q1
H.R. 2055, Consolidated Appropriations Act of 2011 - Lobbied to oppose extending Medicaid rebates to Medicare Part D. Agriculture, Rural Development, FDA and Related Agencies Appropriations Act of 2012 - Lobbied against potential amendments to allow for the importation of unsafe prescription drugs.
S. 668, Health Care Bureaucrats Elimination Act - Lobbied for passage of bill to eliminate the Independent Payment Advisory Board. H.R. 452, Medicare Decisions Accountability Act - Lobbied for passage of bill to eliminate the Independent Payment Advisory Board. Bill not yet introduced, The Medicare Home Infusion Therapy Coverage Act - Lobbied for expanded coverage of home infusion therapy. S. 1454 and H.R. 2969, Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act - Lobbied for extended coverage of immunosuppresive drugs in Medicare. H.R. 2190 and S. 1206, Medicare Drug Savings Act of 2011 - Lobbied to oppose extending Medicaid rebates to Medicare Part D.
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2011 · fourth_quarter · Q4
S. 668, Health Care Bureaucrats Elimination Act - Lobbied for passage of bill to eliminate the Independent Payment Advisory Board. H.R. 452, Medicare Decisions Accountability Act - Lobbied for passage of bill to eliminate the Independent Payment Advisory Board. Bill not yet introduced, The Medicare Home Infusion Therapy Coverage Act - Lobbied for expanded coverage of home infusion therapy. S. 1454 and H.R. 2969, Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act - Lobbied for extended coverage of immunosuppresive drugs in Medicare. H.R. 2190 and S. 1206, Medicare Drug Savings Act of 2011 - Lobbied to oppose extending Medicaid rebates to Medicare Part D.
H.R. 2055, Consolidated Appropriations Act of 2011 - Lobbied to oppose extending Medicaid rebates to Medicare Part D. S. 635, Budget Control Act of 2011 - Lobbied to oppose extending Medicaid rebates to Medicare Part D. Agriculture, Rural Development, FDA and Related Agencies Appropriations Act of 2012 - Lobbied against potential amendments to allow for the importation of unsafe prescription drugs.
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2011 · third_quarter · Q3
S. 668, Health Care Bureaucrats Elimination Act - Lobbied for passage of bill to eliminate the Independent Payment Advisory Board. H.R. 452, Medicare Decisions Accountability Act - Lobbied for passage of bill to eliminate the Independent Payment Advisory Board. Bill not yet introduced, The Medicare Home Infusion Therapy Coverage Act - Lobbied for expanded coverage of home infusion therapy. S. 1454 and H.R. 2969, Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act - Lobbied for extended coverage of immunosuppresive drugs in Medicare. H.R. 2190 and S. 1206, Medicare Drug Savings Act of 2011 - Lobbied to oppose extending Medicaid rebates to Medicare Part D.
S. 365, Budget Control Act of 2011 - Lobbied to oppose extending Medicaid rebates to Part D. NO BILL, Agriculture, Rural Development, FDA and Related Agencies Appropriations Act of 2012 - Lobbied against potential amendments to allow for the importation of unsafe prescription drugs.
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2011 · second_quarter · Q2
S. 668, Health Care Bureaucrats Elimination Act - Lobbied for passage of bill to eliminate the Independent Payment Advisory Board. H.R. 452, Medicare Decisions Accountability Act - Lobbied for passage of bill to eliminate the Independent Payment Advisory Board. Bill not yet introduced, The Medicare Home Infusion Therapy Coverage Act - Lobbied for expanded coverage of home infusion therapy. Bill not yet introduced, Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act - Lobbied for extended coverage of immunosuppresive drugs in Medicare. H.R. 2190 and S. 1206, Medicare Drug Savings Act of 2011 - Lobbied to oppose extending Medicaid rebates to Medicare Part D.
S. 319, Pharmaceutical Market Access and Drug Safety Act - Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. Continuing Resolutions: Lobbied for increased access to HIV/AIDS drugs in the Aids Drug Assistance Program. NO BILL, Health Care Reform Implementation - Lobbied on implementation of provisions in the health care reform bill regarding biosimilars, the Independent Payment Advisory Board and the Annual Fee. S. 752, Lung Cancer Mortality Reduction Act - Lobbied for passage of bill to reduce lung cancer mortality. S. 296, Preserving Access to Life-Savings Medications Act - Lobbied to improve provisions in the drug shortage legislation. H.R. 1483, Drug Safety Enhancement Act of 2011 - Lobbied to pass meaningful import drug shortage legisaltion. NO BILL, Reauthorization of the Prescription Drug User Fee Act - Lobbied for passage of clean PDUFA legislation.
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2011 · first_quarter · 1A
S. 668, Health Care Bureaucrats Elimination Act - Lobbied for passage of bill to eliminate the Independent Payment Advisory Board. H.R. 452, Medicare Decisions Accountability Act - Lobbied for passage of bill to eliminate the Independent Payment Advisory Board. Bill not yet introduced, The Medicare Home Infusion Therapy Coverage Act - Lobbied for expanded coverage of home infusion therapy. Bill not yet introduced, Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act - Lobbied for extended coverage of immunosuppresive drugs in Medicare.
S. 319, Pharmaceutical Market Access and Drug Safety Act - Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. Continuing Resolutions: Lobbied for increased access to HIV/AIDS drugs in the Aids Drug Assistance Program. NO BILL, Health Care Reform Implementation - Lobbied on implementation of provisions in the health care reform bill regarding biosimilars, the Independent Payment Advisory Board and the Annual Fee.
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2011 · first_quarter · Q1
S. 319, Pharmaceutical Market Access and Drug Safety Act - Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. Continuing Resolutions: Lobbied for increased access to HIV/AIDS drugs in the Aids Drug Assistance Program. NO BILL, Health Care Reform Implementation - Lobbied on implementation of provisions in the health care reform bill regarding biosimilars, the Independent Payment Advisory Board and the Annual Fee.
S. 668, Health Care Bureaucrats Elimination Act - Lobbied for passage of bill to eliminate the Independent Payment Advisory Board. H.R. 452, Medicare Decisions Accountability Act - Lobbied for passage of bill to eliminate the Independent Payment Advisory Board. Bill not yet introduced, The Medicare Home Infusion Therapy Coverage Act - Lobbied for expanded coverage of home infusion therapy. Bill not yet introduced, Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act - Lobbied for extended coverage of immunosuppresive drugs in Medicare.
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2010 · fourth_quarter · 4A
H.R. 1298, S. 525 & S. 1232, Pharmaceutical Market Access and Drug Safety Act - Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. H.R. 3081 and H.R. 4899 - Appropriations for AIDS Drug Assistance Program - Lobbied for increased access to HIV/AIDS drugs in the AIDS Drug Assistance Program. H.R. 3974, Viral Hepatitis and Liver Cancer Control and Prevention Act - Lobbied for passage of the bill to increase funding for education, awareness, and surveillance activities related to Viral Hepatitis. H.R. 1438, Promoting increased awareness and diagnosis of peripheral arterial disease (PAD) to address the high mortality rate of this treatable disease - Lobbied to educate members on peripheral arterial disease and for passage of bill. NO BILL, Health Care Reform Implementation - Lobbied on implementation of provisions in the health care reform bill regarding changes to the 340B drug pricing program, the Fee on pharmaceutical sales in government programs, the Independent Payment Advisory Board (IPAB), follow-on biologics, and the Patient-Centered Outcomes Research Institute (PCORI).
Filing targets: HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE, Treasury, Dept of
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2010 · fourth_quarter · 4A
H.R. 1298, S. 525 & S. 1232, Pharmaceutical Market Access and Drug Safety Act - Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. H.R. 3081 and H.R. 4899 - Appropriations for AIDS Drug Assistance Program - Lobbied for increased access to HIV/AIDS drugs in the AIDS Drug Assistance Program. H.R. 3974, Viral Hepatitis and Liver Cancer Control and Prevention Act - Lobbied for passage of the bill to increase funding for education, awareness, and surveillance activities related to Viral Hepatitis. H.R. 1438, Promoting increased awareness and diagnosis of peripheral arterial disease (PAD) to address the high mortality rate of this treatable disease - Lobbied to educate members on peripheral arterial disease and for passage of bill. NO BILL, Health Care Reform Implementation - Lobbied on implementation of provisions in the health care reform bill regarding changes to the 340B drug pricing program, the Fee on pharmaceutical sales in government programs, the Independent Payment Advisory Board (IPAB), follow-on biologics, and the Patient-Centered Outcomes Research Institute (PCORI).
Filing targets: HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE, Treasury, Dept of
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2010 · fourth_quarter · Q4
H.R. 1298, S. 525 & S. 1232, Pharmaceutical Market Access and Drug Safety Act - Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. H.R. 3081 and H.R. 4899 - Appropriations for AIDS Drug Assistance Program - Lobbied for increased access to HIV/AIDS drugs in the AIDS Drug Assistance Program. H.R. 3974, Viral Hepatitis and Liver Cancer Control and Prevention Act - Lobbied for passage of the bill to increase funding for education, awareness, and surveillance activities related to Viral Hepatitis. H.R. 1438, Promoting increased awareness and diagnosis of peripheral arterial disease (PAD) to address the high mortality rate of this treatable disease - Lobbied to educate members on peripheral arterial disease and for passage of bill. NO BILL, Health Care Reform Implementation - Lobbied on implementation of provisions in the health care reform bill regarding changes to the 340B drug pricing program, the Fee on pharmaceutical sales in government programs, the Independent Payment Advisory Board (IPAB), follow-on biologics, and the Patient-Centered Outcomes Research Institute (PCORI).
Filing targets: HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE, Treasury, Dept of
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2010 · fourth_quarter · Q4
H.R. 1298, S. 525 & S. 1232, Pharmaceutical Market Access and Drug Safety Act - Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. H.R. 3081 and H.R. 4899 - Appropriations for AIDS Drug Assistance Program - Lobbied for increased access to HIV/AIDS drugs in the AIDS Drug Assistance Program. H.R. 3974, Viral Hepatitis and Liver Cancer Control and Prevention Act - Lobbied for passage of the bill to increase funding for education, awareness, and surveillance activities related to Viral Hepatitis. H.R. 1438, Promoting increased awareness and diagnosis of peripheral arterial disease (PAD) to address the high mortality rate of this treatable disease - Lobbied to educate members on peripheral arterial disease and for passage of bill. NO BILL, Health Care Reform Implementation - Lobbied on implementation of provisions in the health care reform bill regarding changes to the 340B drug pricing program, the Fee on pharmaceutical sales in government programs, the Independent Payment Advisory Board (IPAB), follow-on biologics, and the Patient-Centered Outcomes Research Institute (PCORI).
Filing targets: HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE, Treasury, Dept of
H.J. Res 59, Continuing Appropriations Resolution, regarding all biopharmaceutical related provisions. Labor, HHS Appropriations, regarding all biopharmaceutical related provisons. Agriculture approrpiations, regarding all biopharmceutical related provisions.H.R. 2725/S. 1413, FDA Safety over Sequestration Act, regarding all biopharmaceutical user-fees. No-bill, educational meetings regarding atrial fibrillation. No bill - regarding FDA regulatory issues and patent incentives related to the 21st Century Cures Initiative. Health Care Reform implementation - regarding essential health benefits coverage and all biopharmaceutical related provisions. H.R. 3723, Viral Hepatitis Testing Act, regarding all provisions.
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
H.R. 2010, S. 1821, legislation reforming Medicare's Sustainable Growth Rate, regarding all provisions.
No Bill, Trade and International Negotiation, regarding intellectual property rights in trade agreements and international negotiations.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
H.R. 1325 and S. 323, "Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2013," regarding all provsions.H.R. 1416, "Cancer Patient Protection Act of 2013," regarding all provisions. H.R. 351 and S. 351, "Protecting Seniors' Access to Medicare Act of 2013," regarding all provisions.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
S.CON.RES.8 and H. Con. Res 25 - Lobbied Members of Congress to oppose: extending Medicaid rebates to Part D; allowing for the importation of pharmaceuticals; and banning patent settlements between brand and generic drug manufacturers.
No Bill, Trade and international IP issues.Lobbied to strengthen intellectual property rights in trade agreements and international negotiations.
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
S.CON.RES.8 and H. CON.RES.25: Lobbied to oppose extending Medicaid rebates to Part D; allowing for the importation of pharmaceuticals and banning patent settlements between brand and generic drug manufacturers. Budget Control Act/Sequester: Lobbied to support appropriate reimbursement for Medicare Part B drugs.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
H.R. 2055, Consolidated Appropriations Act of 2011 - Lobbied to oppose extending Medicaid rebates to Medicare Part D. Agriculture, Rural Development, FDA and Related Agencies Appropriations Act of 2012 - Lobbied against potential amendments to allow for the importation of unsafe prescription drugs.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE, Treasury, Dept of
S. 319, Pharmaceutical Market Access and Drug Safety Act - Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. S. 752, Lung Cancer Mortality Reduction Act of 2011 - Lobbied for passage of bill to reduce lung cancer mortality. NO BILL, Health Care Reform Implementation - Lobbied on implementation of provisions in the health care reform bill regarding biosimilars, the Independent Payment Advisory Board and the Annual Fee. S. 296 and H.R. 2245, Preserving Access to Life-Savings Medications Act - Lobbied to improve provisions in the drug shortage legislation. H.R. 1483, Drug Safety Enhancement Act of 2011 - Lobbied to pass meaningful drug safety legislation. S. 3187, the "Food and Drug Administration Safety and Innovation Act - Lobbied for passage of PDUFA legislation. S. 2113, Transforming the Regulatory Environment to Accelerate Access to Treatments - Lobbied to pass meaningful FDA reform legislation. S. 2236, Advancing Breakthrough Therapies for Patients Act of 2012 - Lobbied to pass meaningful FDA reform legislation. H.R. 4274, BCPA and PREA Reauthorization Act of 2012 - Lobbied for permanence of BCPA and PREA. H.R. 3497, MODERN Cures Act of 2011 - Lobbied for incentives for development of pharmacodiagnostics and dormant therapies. H.R. 3737, Unlocking Lifesaving Treatments for Rare-Diseases Act - Lobbied to pass meaningful FDA reform legislation. H.R. 4132, Faster Access to Specialized Treatments Act - Lobbied to pass meaningful FDA reform legislation. Labor, HHS Appropriations. Lobbied for increased access to HIV/AIDS drugs in the AIDS Drug Assistance Program. NO BILL, Supply chain draft legislation - Lobbied for passage of legisaltion to increase security of the drug distribution supply chain.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE, Treasury, Dept of
S. 319, Pharmaceutical Market Access and Drug Safety Act - Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. S. 752, Lung Cancer Mortality Reduction Act of 2011 - Lobbied for passage of bill to reduce lung cancer mortality. NO BILL, Health Care Reform Implementation - Lobbied on implementation of provisions in the health care reform bill regarding biosimilars, the Independent Payment Advisory Board and the Annual Fee. S. 296 and H.R. 2245, Preserving Access to Life-Savings Medications Act - Lobbied to improve provisions in the drug shortage legislation. H.R. 1483, Drug Safety Enhancement Act of 2011 - Lobbied to pass meaningful drug safety legislation. S. 3187, the "Food and Drug Administration Safety and Innovation Act - Lobbied for passage of PDUFA legislation. S. 2113, Transforming the Regulatory Environment to Accelerate Access to Treatments - Lobbied to pass meaningful FDA reform legislation. S. 2236, Advancing Breakthrough Therapies for Patients Act of 2012 - Lobbied to pass meaningful FDA reform legislation. H.R. 4274, BCPA and PREA Reauthorization Act of 2012 - Lobbied for permanence of BCPA and PREA. H.R. 3497, MODERN Cures Act of 2011 - Lobbied for incentives for development of pharmacodiagnostics and dormant therapies. H.R. 3737, Unlocking Lifesaving Treatments for Rare-Diseases Act - Lobbied to pass meaningful FDA reform legislation. H.R. 4132, Faster Access to Specialized Treatments Act - Lobbied to pass meaningful FDA reform legislation. Labor, HHS Appropriations. Lobbied for increased access to HIV/AIDS drugs in the AIDS Drug Assistance Program.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE, Treasury, Dept of
S. 668, Health Care Bureaucrats Elimination Act - Lobbied for passage of bill to eliminate the Independent Payment Advisory Board. H.R. 452, Medicare Decisions Accountability Act - Lobbied for passage of bill to eliminate the Independent Payment Advisory Board. Bill not yet introduced, The Medicare Home Infusion Therapy Coverage Act - Lobbied for expanded coverage of home infusion therapy. S. 1454 and H.R. 2969, Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act - Lobbied for extended coverage of immunosuppresive drugs in Medicare. H.R. 2190 and S. 1206, Medicare Drug Savings Act of 2011 - Lobbied to oppose extending Medicaid rebates to Medicare Part D.
H.R. 2055, Consolidated Appropriations Act of 2011 - Lobbied to oppose extending Medicaid rebates to Medicare Part D. Agriculture, Rural Development, FDA and Related Agencies Appropriations Act of 2012 - Lobbied against potential amendments to allow for the importation of unsafe prescription drugs.
Filing targets: HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE, Treasury, Dept of
H.R. 2055, Consolidated Appropriations Act of 2011 - Lobbied to oppose extending Medicaid rebates to Medicare Part D. Agriculture, Rural Development, FDA and Related Agencies Appropriations Act of 2012 - Lobbied against potential amendments to allow for the importation of unsafe prescription drugs.
Filing targets: HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE, Treasury, Dept of
S. 319, Pharmaceutical Market Access and Drug Safety Act - Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. S. 752, Lung Cancer Mortality Reduction Act of 2011 - Lobbied for passage of bill to reduce lung cancer mortality. NO BILL, Health Care Reform Implementation - Lobbied on implementation of provisions in the health care reform bill regarding biosimilars, the Independent Payment Advisory Board and the Annual Fee. S. 296 and H.R. 2245, Preserving Access to Life-Savings Medications Act - Lobbied to improve provisions in the drug shortage legislation. H.R. 1483, Drug Safety Enhancement Act of 2011 - Lobbied to pass meaningful drug safety legislation. NO BILL, Reauthorization of the Prescription Drug User Fee Act - Lobbied for passage of clean PDUFA legislation. Labor, HHS Appropriations - Lobbied for increased access to HIV/AIDS drugs in the AIDS Drug Assistance Program. S. 2113, Transforming the Regulatory Environment to Accelerate Access to Treatments - Lobbied to pass meaningful FDA reform legislation. S. 2236, Advancing Breakthrough Therapies for Patients Act of 2012 - Lobbied to pass meaningful FDA reform legislation. H.R. 4274, BCPA and PREA Reauthorization Act of 2012 - Lobbied for permanence of BCPA and PREA. H.R. 3497, MODERN Cures Act of 2011 - Lobbied for incentives for development of pharmacodiagnostics and dormant therapies. H.R. 3737, Unlocking Lifesaving Treatments for Rare-Diseases Act - Lobbied to pass meaningful FDA reform legislation. H.R. 4132, Faster Access to Specialized Treatments Act - Lobbied to pass meaningful FDA reform legislation.
Filing targets: HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE, Treasury, Dept of
S. 319, Pharmaceutical Market Access and Drug Safety Act - Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. S. 752, Lung Cancer Mortality Reduction Act of 2011 - Lobbied for passage of bill to reduce lung cancer mortality. NO BILL, Health Care Reform Implementation - Lobbied on implementation of provisions in the health care reform bill regarding biosimilars, the Independent Payment Advisory Board and the Annual Fee. S. 296 and H.R. 2245, Preserving Access to Life-Savings Medications Act - Lobbied to improve provisions in the drug shortage legislation. H.R. 1483, Drug Safety Enhancement Act of 2011 - Lobbied to pass meaningful drug safety legislation. NO BILL, Reauthorization of the Prescription Drug User Fee Act - Lobbied for passage of clean PDUFA legislation. Labor, HHS Appropriations - Lobbied for increased access to HIV/AIDS drugs in the AIDS Drug Assistance Program. S. 2113, Transforming the Regulatory Environment to Accelerate Access to Treatments - Lobbied to pass meaningful FDA reform legislation. S. 2236, Advancing Breakthrough Therapies for Patients Act of 2012 - Lobbied to pass meaningful FDA reform legislation. H.R. 4274, BCPA and PREA Reauthorization Act of 2012 - Lobbied for permanence of BCPA and PREA. H.R. 3497, MODERN Cures Act of 2011 - Lobbied for incentives for development of pharmacodiagnostics and dormant therapies. H.R. 3737, Unlocking Lifesaving Treatments for Rare-Diseases Act - Lobbied to pass meaningful FDA reform legislation. H.R. 4132, Faster Access to Specialized Treatments Act - Lobbied to pass meaningful FDA reform legislation.
Filing targets: HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE, Treasury, Dept of
S. 319, Pharmaceutical Market Access and Drug Safety Act - Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. S. 752, Lung Cancer Mortality Reduction Act of 2011 - Lobbied for passage of bill to reduce lung cancer mortality. NO BILL, Health Care Reform Implementation - Lobbied on implementation of provisions in the health care reform bill regarding biosimilars, the Independent Payment Advisory Board and the Annual Fee. S. 296 and H.R. 2245, Preserving Access to Life-Savings Medications Act - Lobbied to improve provisions in the drug shortage legislation. H.R. 1483, Drug Safety Enhancement Act of 2011 - Lobbied to pass meaningful drug safety legislation. NO BILL, Reauthorization of the Prescription Drug User Fee Act - Lobbied for passage of clean PDUFA legislation. Labor, HHS Appropriations - Lobbied for increased access to HIV/AIDS drugs in the AIDS Drug Assistance Program.
Filing targets: HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE, Treasury, Dept of
S. 319, Pharmaceutical Market Access and Drug Safety Act - Lobbied against passage of legislation to allow for the importation of unsafe prescription drugs. Continuing Resolutions - Lobbied for increased access to HIV/AIDS drugs in the AIDS Drug Assistance Program. NO BILL, Health Care Reform Implementation - Lobbied on implementation of provisions in the health care reform bill regarding biosimilars, the Independent Payment Advisory Board and the Annual Fee. S. 752, Lung Cancer Mortality Reduction Act - Lobbied for passage of bill to reduce lung cancer mortality. S. 296 and H.R. 2245, Preserving Access to Life-Savings Medications Act - Lobbied to improve provisions in the drug shortage legislation. H.R. 1483, Drug Safety Enhancement Act of 2011 - Lobbied to pass meaningful drug safety legisaltion. NO BILL, Reauthorization of the Prescription Drug User Fee Act - Lobbied for passage of clean PDUFA legislation.
Filing targets: HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE, Treasury, Dept of
Filing targets: HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE, Treasury, Dept of
Filing targets: HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE, Treasury, Dept of
Filing targets: HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE, Treasury, Dept of